News

EconoTimes49m
Roche Halts Elevidys Dosing in Some Duchenne Patients After Fatalities
Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory ...
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...
The American Journal of Managed Care3d
RGX-202 Gene Therapy Improves DMD Trajectory, Biomarkers
Participants with Duchenne muscular dystrophy (DMD) who received RGX-202 demonstrated functional improvement and better ...
RTÉ Ireland4d
Families call for approval of new 'game changer' Muscular Dystrophy drug
Parents of children with an incurable muscle-wasting condition have called on the Minister for Health to accelerate the ...
New hope for Deal family of nine-year-old boy with Duchenne muscular dystrophy
The parents of a nine-year-old boy battling a devastating muscle-wasting condition say new research could offer them more ...
Managed Healthcare Executive12d
Encouraging Results from Phase 1 Trials, Says Satellos Chief Scientific Officer. Now It's On to Phase 2
Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support ...
Medical Marketing & Media6d
How the Muscular Dystrophy Association celebrated 75 years of research
The campaign to commemorate the work of the Muscular Dystrophy Association was created in partnership with agency Yes&.